Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE4.6500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 4.6500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 4138 | 4.85 |
| 09:35 ET | 100 | 4.8612 |
| 09:39 ET | 350 | 4.9486 |
| 09:42 ET | 1100 | 4.92 |
| 09:44 ET | 1020 | 4.88 |
| 09:46 ET | 2277 | 4.85 |
| 09:48 ET | 1304 | 4.86 |
| 09:50 ET | 843 | 4.88 |
| 09:51 ET | 337 | 4.87 |
| 09:57 ET | 32407 | 4.81 |
| 10:00 ET | 1100 | 4.785 |
| 10:02 ET | 571 | 4.8 |
| 10:04 ET | 200 | 4.78 |
| 10:06 ET | 1190 | 4.76 |
| 10:08 ET | 12066 | 4.7015 |
| 10:09 ET | 3345 | 4.75 |
| 10:11 ET | 1633 | 4.73 |
| 10:13 ET | 1029 | 4.73 |
| 10:15 ET | 2340 | 4.73 |
| 10:18 ET | 3755 | 4.71 |
| 10:20 ET | 500 | 4.71 |
| 10:22 ET | 300 | 4.71 |
| 10:24 ET | 1901 | 4.71 |
| 10:26 ET | 200 | 4.72 |
| 10:27 ET | 200 | 4.71 |
| 10:29 ET | 1780 | 4.71 |
| 10:31 ET | 986 | 4.72 |
| 10:33 ET | 585 | 4.71 |
| 10:36 ET | 100 | 4.71 |
| 10:38 ET | 805 | 4.71 |
| 10:40 ET | 9552 | 4.71 |
| 10:42 ET | 300 | 4.71 |
| 10:44 ET | 1386 | 4.71 |
| 10:45 ET | 1629 | 4.71 |
| 10:47 ET | 8004 | 4.62 |
| 10:49 ET | 5833 | 4.67 |
| 10:51 ET | 4575 | 4.705 |
| 10:54 ET | 500 | 4.71 |
| 10:58 ET | 9152 | 4.685 |
| 11:00 ET | 3645 | 4.7533 |
| 11:02 ET | 1382 | 4.7 |
| 11:03 ET | 2407 | 4.72 |
| 11:05 ET | 590 | 4.73 |
| 11:07 ET | 700 | 4.71 |
| 11:09 ET | 797 | 4.7217 |
| 11:12 ET | 711 | 4.72 |
| 11:14 ET | 1086 | 4.72 |
| 11:16 ET | 629 | 4.7 |
| 11:18 ET | 3102 | 4.7 |
| 11:20 ET | 809 | 4.7 |
| 11:21 ET | 194 | 4.7 |
| 11:23 ET | 1540 | 4.7 |
| 11:30 ET | 164 | 4.715 |
| 11:32 ET | 108 | 4.715 |
| 11:34 ET | 200 | 4.715 |
| 11:36 ET | 2059 | 4.71 |
| 11:38 ET | 2764 | 4.715 |
| 11:39 ET | 561 | 4.71 |
| 11:41 ET | 1580 | 4.7 |
| 11:43 ET | 314 | 4.71 |
| 11:45 ET | 1786 | 4.7 |
| 11:48 ET | 1025 | 4.7 |
| 11:50 ET | 3369 | 4.72 |
| 11:52 ET | 466 | 4.71 |
| 11:54 ET | 300 | 4.71 |
| 11:56 ET | 330 | 4.7 |
| 11:57 ET | 350 | 4.7 |
| 11:59 ET | 344 | 4.71 |
| 12:01 ET | 100 | 4.71 |
| 12:06 ET | 315 | 4.72 |
| 12:10 ET | 175 | 4.715 |
| 12:14 ET | 3183 | 4.8 |
| 12:15 ET | 800 | 4.74 |
| 12:17 ET | 200 | 4.75 |
| 12:19 ET | 700 | 4.76 |
| 12:21 ET | 268 | 4.75 |
| 12:24 ET | 200 | 4.74 |
| 12:26 ET | 100 | 4.74 |
| 12:28 ET | 100 | 4.74 |
| 12:30 ET | 494 | 4.73 |
| 12:37 ET | 1324 | 4.73 |
| 12:39 ET | 100 | 4.72 |
| 12:46 ET | 260 | 4.71 |
| 12:50 ET | 100 | 4.71 |
| 12:51 ET | 2496 | 4.7 |
| 12:53 ET | 1384 | 4.7 |
| 12:55 ET | 210 | 4.7015 |
| 12:57 ET | 471 | 4.72 |
| 01:00 ET | 395 | 4.71 |
| 01:02 ET | 300 | 4.72 |
| 01:04 ET | 702 | 4.7 |
| 01:06 ET | 821 | 4.7 |
| 01:08 ET | 162 | 4.7 |
| 01:09 ET | 455 | 4.71 |
| 01:11 ET | 201 | 4.7 |
| 01:13 ET | 136 | 4.7 |
| 01:15 ET | 131 | 4.7 |
| 01:20 ET | 100 | 4.7 |
| 01:22 ET | 234 | 4.7 |
| 01:24 ET | 568 | 4.7 |
| 01:26 ET | 622 | 4.68 |
| 01:27 ET | 200 | 4.7 |
| 01:29 ET | 1202 | 4.71 |
| 01:31 ET | 500 | 4.71 |
| 01:33 ET | 1100 | 4.72 |
| 01:36 ET | 26223 | 4.71 |
| 01:38 ET | 2400 | 4.73 |
| 01:40 ET | 945 | 4.71 |
| 01:42 ET | 549 | 4.702 |
| 01:44 ET | 2450 | 4.7 |
| 01:45 ET | 400 | 4.7 |
| 01:47 ET | 2424 | 4.69 |
| 01:49 ET | 4022 | 4.6801 |
| 01:51 ET | 4850 | 4.67 |
| 01:54 ET | 395 | 4.67 |
| 01:56 ET | 1786 | 4.675 |
| 01:58 ET | 3848 | 4.69 |
| 02:00 ET | 6385 | 4.69 |
| 02:02 ET | 1423 | 4.69 |
| 02:03 ET | 4436 | 4.69 |
| 02:05 ET | 221 | 4.67 |
| 02:07 ET | 100 | 4.67 |
| 02:09 ET | 5072 | 4.65 |
| 02:12 ET | 200 | 4.65 |
| 02:14 ET | 212 | 4.655 |
| 02:16 ET | 418 | 4.6565 |
| 02:20 ET | 1794 | 4.65 |
| 02:21 ET | 1477 | 4.64 |
| 02:23 ET | 3400 | 4.62 |
| 02:25 ET | 120 | 4.62 |
| 02:27 ET | 901 | 4.62 |
| 02:30 ET | 6079 | 4.65 |
| 02:32 ET | 1641 | 4.64 |
| 02:34 ET | 604 | 4.65 |
| 02:38 ET | 100 | 4.65 |
| 02:48 ET | 12973 | 4.6 |
| 02:50 ET | 990 | 4.55 |
| 02:52 ET | 4275 | 4.54 |
| 02:54 ET | 1566 | 4.56 |
| 02:56 ET | 300 | 4.55 |
| 02:57 ET | 669 | 4.56 |
| 02:59 ET | 1987 | 4.53 |
| 03:01 ET | 1350 | 4.55 |
| 03:03 ET | 10664 | 4.555 |
| 03:06 ET | 1144 | 4.52 |
| 03:08 ET | 2282 | 4.6 |
| 03:10 ET | 2548 | 4.63 |
| 03:12 ET | 1631 | 4.63 |
| 03:14 ET | 23484 | 4.59 |
| 03:15 ET | 370 | 4.59 |
| 03:17 ET | 397 | 4.58 |
| 03:19 ET | 2059 | 4.58 |
| 03:21 ET | 1778 | 4.6 |
| 03:24 ET | 1580 | 4.6 |
| 03:26 ET | 2560 | 4.5807 |
| 03:28 ET | 1300 | 4.58 |
| 03:32 ET | 3524 | 4.59 |
| 03:33 ET | 1387 | 4.6 |
| 03:35 ET | 1408 | 4.606 |
| 03:37 ET | 5299 | 4.5879 |
| 03:39 ET | 898 | 4.58 |
| 03:42 ET | 1992 | 4.58 |
| 03:44 ET | 5343 | 4.57 |
| 03:46 ET | 2194 | 4.58 |
| 03:48 ET | 386 | 4.58 |
| 03:50 ET | 5426 | 4.62 |
| 03:51 ET | 4961 | 4.61 |
| 03:53 ET | 940 | 4.625 |
| 03:55 ET | 4559 | 4.62 |
| 03:57 ET | 2152 | 4.63 |
| 04:00 ET | 27788 | 4.65 |
Nov 7, 2024
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Oct 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 155.0M | -2.7x | --- |
Ventyx Biosciences Inc | 155.5M | -0.9x | --- |
Checkpoint Therapeutics Inc | 151.7M | -2.1x | --- |
Achieve Life Sciences Inc | 159.0M | -4.0x | --- |
Cytodyn Inc | 150.0M | -5.3x | --- |
Outlook Therapeutics Inc | 149.5M | -0.8x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Chief Medical Officer
- W. Garrett Nichols
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $149.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.94 |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
